A dual-adjuvanting strategy for peptide-based subunit vaccines against group A Streptococcus: Lipidation and polyelectrolyte complexes

2020 ◽  
Vol 28 (24) ◽  
pp. 115823 ◽  
Author(s):  
Lili Zhao ◽  
Jieru Yang ◽  
Ummey Jannatun Nahar ◽  
Zeinab G. Khalil ◽  
Robert J. Capon ◽  
...  
Keyword(s):  
Group A Streptococcus ◽  
Subunit Vaccines ◽  
Polyelectrolyte Complexes ◽  
Group A

scholarly journals Development of Polyelectrolyte Complexes for the Delivery of Peptide-Based Subunit Vaccines against Group A Streptococcus

Nanomaterials ◽  
2020 ◽  
Vol 10 (5) ◽  
pp. 823 ◽  
Author(s):  
Lili Zhao ◽  
Wanli Jin ◽  
Jazmina Gonzalez Cruz ◽  
Nirmal Marasini ◽  
Zeinab G. Khalil ◽  
...  
Keyword(s):  
Immune Responses ◽  
Subunit Vaccine ◽  
Group A Streptococcus ◽  
Vaccine Delivery ◽  
Surface Charges ◽  
Subunit Vaccines ◽  
Polyelectrolyte Complexes ◽  
Humoral Immune ◽  
Anionic Polymers ◽  
Group A

Peptide subunit vaccines hold great potential compared to traditional vaccines. However, peptides alone are poorly immunogenic. Therefore, it is of great importance that a vaccine delivery platform and/or adjuvant that enhances the immunogenicity of peptide antigens is developed. Here, we report the development of two different systems for the delivery of lipopeptide subunit vaccine (LCP-1) against group A streptococcus: polymer-coated liposomes and polyelectrolyte complexes (PECs). First, LCP-1-loaded and alginate/trimethyl chitosan (TMC)-coated liposomes (Lip-1) and LCP-1/alginate/TMC PECs (PEC-1) were examined for their ability to trigger required immune responses in outbred Swiss mice; PEC-1 induced stronger humoral immune responses than Lip-1. To further assess the adjuvanting effect of anionic polymers in PECs, a series of PECs (PEC-1 to PEC-5) were prepared by mixing LCP-1 with different anionic polymers, namely alginate, chondroitin sulfate, dextran, hyaluronic acid, and heparin, then coated with TMC. All produced PECs had similar particle sizes (around 200 nm) and surface charges (around + 30 mV). Notably, PEC-5, which contained heparin, induced higher antigen-specific systemic IgG and mucosal IgA titers than all other PECs. PEC systems, especially when containing heparin and TMC, could function as a promising platform for peptide-based subunit vaccine delivery for intranasal administration.

scholarly journals Immunogenicity Assessment of Different Segments and Domains of Group A Streptococcal C5a Peptidase and Their Application Potential as Carrier Protein for Glycoconjugate Vaccine Development

Vaccines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 139
Author(s):  
Guirong Wang ◽  
Jielin Zhao ◽  
Yisheng Zhao ◽  
Subo Wang ◽  
Shaojie Feng ◽  
...  
Keyword(s):  
Vaccine Development ◽  
Group A Streptococcus ◽  
Carrier Protein ◽  
Cell Surfaces ◽  
Gas Cell ◽  
Subunit Vaccines ◽  
Immunogenicity Assessment ◽  
Group A ◽  
Application Potential ◽  
Glycoconjugate Vaccine

Group A streptococcal C5a peptidase (ScpA) is a highly conserved surface virulence factor present on group A streptococcus (GAS) cell surfaces. It has attracted much more attention as a promising antigenic target for GAS vaccine development due to its high antigenicity to stimulate specific and immunoprotective antibodies. In this study, a series of segments of ScpA were rationally designed according to the functional domains described in its crystal structure, efficiently prepared and immunologically evaluated so as to assess their potential as antigens for the development of subunit vaccines. Immunological studies revealed that Fn, Fn2, and rsScpA193 proteins were promising antigen candidates worthy for further exploration. In addition, the potential of Fn and Fn2 as carrier proteins to formulate effective glycoconjugate vaccine was also investigated.

scholarly journals Opsonic Activity of Conservative Versus Variable Regions of the Group A Streptococcus M Protein

Vaccines ◽  
2020 ◽  
Vol 8 (2) ◽  
pp. 210
Author(s):  
Chuankai Dai ◽  
Zeinab G. Khalil ◽  
Waleed M. Hussein ◽  
Jieru Yang ◽  
Xiumin Wang ◽  
...  
Keyword(s):  
Vaccine Development ◽  
Group A Streptococcus ◽  
Clinical Isolates ◽  
M Protein ◽  
Opsonic Activity ◽  
Subunit Vaccines ◽  
Variable Regions ◽  
Global Challenge ◽  
Group A ◽  
Outbred Mice

Group A Streptococcus (GAS) and GAS-associated infections are a global challenge, with no licensed GAS vaccine on the market. The GAS M protein is a critical virulence factor in the fight against GAS infection, and it has been a primary target for GAS vaccine development. Measuring functional opsonic antibodies against GAS is an important component in the clinical development path for effective vaccines. In this study, we compared the opsonic activity of two synthetic, self-adjuvanting subunit vaccines containing either the J8- or 88/30-epitope in Swiss outbred mice using intranasal administration. Following primary immunization and three boosts, sera were assessed for IgG activity using ELISA, and opsonization activity against seven randomly selected clinical isolates of GAS was measured. Vaccine constructs containing the conservative J8-epitope showed significant opsonic activity against six out of the seven GAS clinical isolates, while the vaccine containing the variable 88/30-epitope did not show any significant opsonic activity.

Etiology, clinical presentation, laboratory diagnostics, pathogenesis of impetigo and treatment methods

2020 ◽  
pp. 64-70
Author(s):  
Anastasiya Laknitskaya
Keyword(s):  
Streptococcus Pyogenes ◽  
Skin Diseases ◽  
Group A Streptococcus ◽  
Antibiotic Sensitivity ◽  
Antioxidant Defense System ◽  
Laboratory Diagnostics ◽  
Treatment Methods ◽  
Group A ◽  
The Individual

Currently, one of the priority medical and social problems is the optimization of treatment methods for pyoderma associated with Streptococcus pyogenes — group A streptococcus (GAS). To date, the proportion of pyoderma, the etiological factor of which is Streptococcus pyogenes, is about 6 % of all skin diseases and is in the range from 17.9 to 43.9 % of all dermatoses. Role of the bacterial factor in the development of streptococcal pyoderma is obvious. Traditional treatment complex includes antibacterial drugs selected individually, taking into account the antibiotic sensitivity of pathognomonic bacteria, and it is not always effective. Currently implemented immunocorrection methods often do not take into account specific immunological features of the disease, the individual, and the fact that the skin performs the function of not only a mechanical barrier, but it is also an immunocompetent organ. Such an approach makes it necessary to conduct additional studies clarifying the role of factors of innate and adaptive immunity, intercellular mediators and antioxidant defense system, that allow to optimize the treatment of this pathology.

Sign in / Sign up

Export Citation Format

Share Document